News from novo nordisk A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 14, 2023, 08:30 ET Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024

Novo Nordisk Inc. today announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with type 1 and type ...

Jan 12, 2023, 20:28 ET Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved a label update for Rybelsus® (semaglutide) tablets 7 mg or 14 mg, allowing use as a...

Mar 28, 2022, 18:37 ET Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a...

Nov 05, 2021, 08:46 ET Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity

Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™...

Nov 05, 2021, 08:45 ET Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity

Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™...

Nov 05, 2021, 08:45 ET Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity

Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™...

Jun 26, 2021, 16:30 ET Investigational 2 mg Dose of Ozempic® (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic® 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial

Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant...

Jun 16, 2021, 09:07 ET Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions

Novo Nordisk announced that new data from more than 30 abstracts will be presented from the company's approved and investigational medicines...

Jun 04, 2021, 15:46 ET Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide)...

May 17, 2021, 12:30 ET Ziltivekimab reduced inflammatory biomarkers associated with atherosclerosis in people with chronic kidney disease in phase 2 trial

Novo Nordisk today presented results from RESCUE, a phase 2 randomised, double-blind, placebo controlled clinical trial assessing the effect of...

May 13, 2021, 01:00 ET Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities

Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for...

May 07, 2021, 15:42 ET Novo Nordisk issues voluntary nationwide recall of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy® product samples due to improper storage temperature conditions

Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the...

Mar 26, 2021, 09:22 ET Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended ...

Mar 23, 2021, 15:45 ET Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous...

Mar 23, 2021, 14:17 ET Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

New results from the STEP phase 3a clinical trial program demonstrated weight loss with investigational treatment of once-weekly subcutaneous...

Mar 15, 2021, 09:23 ET Data from STEP clinical trial program evaluating effect of semaglutide 2.4 mg in people with obesity to be presented at 2021 ENDO annual meeting

Novo Nordisk today announced that results from three trials from the pivotal STEP (Semaglutide Treatment Effect in People with obesity) phase 3...

Jan 13, 2021, 09:38 ET Cities Changing Diabetes announces five new programs to fight diabetes and obesity in Philadelphia

Five innovative community-based programs have been selected to receive preliminary funding to help combat diabetes and obesity in Philadelphia...

Jan 04, 2021, 09:14 ET Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com

Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance...

Dec 04, 2020, 21:33 ET FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for ...

Nov 05, 2020, 10:06 ET Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy

Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural...

Sep 24, 2020, 06:28 ET Umstellung von anderen Basalinsulinen auf einmal wöchentlich verabreichtes Insulin Icodec hat sich in Phase 2-Studie bei Menschen mit Typ-2-Diabetes als wirkungsvoll und gut verträglich erwiesen

Novo Nordisk gab heute die Ergebnisse von drei klinischen Phase-2-Studien für Insulin Icodec, ein einmal wöchentlich zu verabreichendes...

Sep 24, 2020, 06:20 ET Le passage à l'insuline icodec expérimentale à prise hebdomadaire à partir d'autres insulines basales s'avère efficace et bien toléré chez les personnes atteintes de diabète de type 2 au cours d'un essai de phase II

BAGSVÆRD, Danemark, 24 septembre 2020 /PRNewswire/ – Aujourd'hui, Novo Nordisk a annoncé les résultats de trois essais cliniques de phase II sur...

Sep 24, 2020, 01:23 ET El cambio a la insulina icodec de administración semanal y en etapa de investigación desde otras insulinas basales demostró ser eficaz y bien tolerado para pacientes con diabetes tipo 2 en un ensayo clínico de fase 2

Novo Nordisk anunció hoy los resultados de tres ensayos clínicos de fase 2 de la insulina icodec, un análogo de insulina basal de administración...

Sep 24, 2020, 01:23 ET A mudança de outras insulinas basais para a insulina sob investigação icodec uma vez por semana demonstrou ser eficaz e bem tolerada por pessoas com diabetes tipo 2 em um estudo clínico de fase 2

Hoje, a Novo Nordisk anunciou os resultados de três estudos clínicos de fase 2 com a insulina icodec, um análogo sob investigação da insulina basal...

Sep 22, 2020, 15:22 ET El cambio a insulina icodec desde otras insulinas basales es eficaz y bien tolerada para la diabetes de tipo 2

Hoy, Novo Nordisk anunció los resultados de los tres ensayos clínicos de fase 2 para insulina icodec, un análogo de insulina basal una vez por...